ArticleJournal of ovarian research2019
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Eleonora Ghisoni et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it